April 10, 2020 – This policy brief discusses the impact of underfunding TB research led by U.S. government agencies. The brief explores several prospective opportunities for TB R&D that would be made possible with increased funding, with recommendations on where policymakers and appropriators can make key investments to U.S. government agencies to advance crucial science on TB diagnostics, treatments, and vaccines.